Experimental antibody targets Tough-to-Treat skin cancer in early trial
NCT ID NCT07213882
Summary
This early-stage trial is testing a new antibody called DT-7012 for people with advanced cutaneous T-cell lymphoma (CTCL), a type of skin cancer, that has come back or hasn't responded to at least two previous treatments. The study aims to find a safe dose and see if the antibody can help reduce the cancer by targeting a specific protein on the cancer cells. It will enroll about 30 adults to monitor side effects and initial signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.